RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo could shrink head and neck tumors before surgery
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink tumors more than the immunotherapy alone in people with stage III-IV head and neck cancer. About 44 participants will receive either the combination …
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:41 UTC
-
New combo attack on recurrent head & neck cancer: immunotherapy plus radiation before surgery
Disease control Recruiting nowThis early-phase trial is for people with head and neck cancer that has persisted or returned after prior treatment. It tests whether giving the immunotherapy drug pembrolizumab along with radiation before and during surgery can help kill more cancer cells. The main goals are to …
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study compares two treatments for head and neck cancer that has returned or spread and no longer responds to standard platinum chemotherapy. One group gets the immunotherapy drug pembrolizumab alone; the other gets pembrolizumab plus cetuximab, which targets a protein on can…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
New vaccine combo aims to rally immune system against advanced head and neck cancer
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for head and neck cancer that has returned or spread. The study aims to find the safest dose and check for side effects in about 40…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC
-
Remote hearing checks could save cancer Patients' ears
Knowledge-focused Recruiting nowThis study looks at whether offering hearing tests close to home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy (cisplatin) and radiation can cause hearing loss, but many patients skip follow-up tests. The study will…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:52 UTC